Experiments on rodents have shown that CYP1B1 contributes to the development of (i) the hypertension caused by angiotensin II administration and (ii) the associated pathophysiological changes: cardiac hypertrophy, an enhanced vascular response to vasoconstrictors, the increased production of reactive oxygen species, and endothelial dysfunction [28,29]. The gene discussed is CYP1B1; the disease is hypertensive disorder.